Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib
Figure 1
Schematic representation of ERBB2 mutations analyzed.
(A and B) The side chains of mutants considered in this study are plotted (red sticks) together with a schematic representation of the protein fold using the crystal structure of EGFR kinase in complex with erlotinib (green sticks). B) is a view roughly orthogonal to A) and shows additional inhibitors gefitinib (yellow sticks) and lapatinib (blue sticks) superimposed at the ATP binding site.